Hypertension Diagnostics, Inc. Newsroom


	Hypertension Diagnostics Extends Warrant Offering and Class A Warrant to November 14, 2002; Exercise Price of Both Class A Warrant and Class B Warrant Reduced to $1.00 ST. PAUL, MN – October 17, 2002 – Hypertension Diagnostics, Inc., (NASDAQ SmallCap: HDII) announced today that it has extended the period during which holders of the Company’s Redeemable Class A Warrants (the “Class A Warrants”) (NASDAQ SmallCap: HDIIW) may participate in the Company’s offering of up to 2,356,073 Redeemable Class B Warrants (the “Class B Warrants”) (NASDAQ SmallCap: HDIIZ). The offering period began on June 6, 2002. The expiration of the offering period has been extended from 5:00 p.m. Central Time on October 22, 2002 to 5:00 p.m. Central Time on November 14, 2002. Holders of the Company’s outstanding Class A Warrants who properly exercise a Class A Warrant during the offering period will be issued one Class B Warrant for each Class A Warrant exercised. In connection with this extended offering period, the Company has likewise extended the expiration date of the Class A Warrant from 5:00 p.m. Central Time on October 22, 2002 to 5:00 p.m. Central Time on November 14, 2002.
	The Company also announced that effective today the exercise prices of both the Class A Warrant and the Class B Warrant have been reduced from $1.25 and $1.50, respectively, to $1.00 per share of Common Stock issuable upon exercise. The reductions in exercise price will continue until the expirations of the Class A Warrant and the Class B Warrant on November 14, 2002 and January 23, 2006, respectively. For a copy of the prospectus and prospectus supplements please contact: Hypertension Diagnostics, Inc. 2915 Waters Road, Suite 108 Eagan, Minnesota 55121-1562 (651) 687-9999 (ext. 106) Attention: James S. Murphy A registration statement relating to this offering was declared effective by the U.S. Securities and Exchange Commission on June 6, 2002. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company’s 2002 Annual Report on Form 10-KSB under the caption “Risk Factors,” as well as others not now anticipated. CVProfilor is a registered trademark of Hypertension Diagnostics, Inc. Hypertension Diagnostics, HDI/PulseWave, PulseWave and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved. Contact: Greg H. Guettler, President Return to the Main HDI Newsroom Back to Top

Copyright © 2009 Hypertension Diagnostics, Inc Last revised Wednesday February 11, 2009 HDI Legal Information